|
| ID |
DDInter1036 |
| Drug Type |
small molecule |
| Molecular Formula |
C21H19Cln4O4 |
| Molecular Weight |
426.860
|
| Description |
Lenvatinib is a receptor tyrosine kinase inhibitor used for the treatment of metastatic thyroid cancer, advanced renal cell carcinoma in combination with everolimus, and unresectable hepatocellular carcinoma.
|
| ATC Classification |
L01XE29
|
| IUPAC Name |
4-{3-Chloro-4-[(Cyclopropylcarbamoyl)Amino]Phenoxy}-7-Methoxyquinoline-6-Carboxamide |
| InChI |
Inchi=1S/C21H19Cln4O4/C1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/H4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28) |
| InChI Key |
WOSKHXYHFSIKNG-UHFFFAOYSA-N |
| Canonical SMILES |
COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O |
| Useful Links |
DrugBank
ChEMBL
PubChem
|